Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 4/20 | 0.67 |
| ▸ | CASP3 | P42574 | 5/20 | 0.65 |
| ▸ | CASP7 | P55210 | 3/20 | 0.65 |
| ▸ | REN | P00797 | 3/20 | 0.61 |
| ▸ | CASP9 | P55211 | 2/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18092847 | 0.91 | CASP1 (0.66) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL17557404 | 0.90 | CASP1 (0.67) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL3488773 | 0.90 | CASP1 (0.71) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL2034510 | 0.88 | CASP1 (0.67) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL2043035 | 0.88 | CASP1 (0.67) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL2037941 | 0.87 | CASP1 (0.67) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL5491506 | 0.85 | CASP1 (0.65) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL5686620 | 0.84 | REN (0.65) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL17577587 | 0.83 | REN (0.68) | CASP1CASP3CASP7RENCASP9 | |
| SCHEMBL17558194 | 0.83 | REN (0.68) | CASP1CASP3CASP7RENCASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068580-A1 | METHOD FOR TREATMENT OF GM1 GANGLIOSIDOSIS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-03-10 | — | — | US | claimed |
| US-10035830-B2 | Method for treatment of GM1 gangliosidosis | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2018-07-31 | — | — | US | disclosed |
| US-20160068580-A1 | METHOD FOR TREATMENT OF GM1 GANGLIOSIDOSIS | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035830-B2 | Method for treatment of GM1 gangliosidosis | GBA1, MAN2B1, GBA2 | CASP1 109/4885CASP3 887/4885CASP7 1195/4885 |
| US-20160068580-A1 | METHOD FOR TREATMENT OF GM1 GANGLIOSIDOSIS | GBA1, MAN2B1, GBA2 | CASP1 130/4885CASP3 788/4885CASP7 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.